Question 1

What is Vertex Pharmaceuticals's P/E ratio?

Accepted Answer

Vertex Pharmaceuticals (VRTX) P/E ratio is 27.9× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Vertex Pharmaceuticals?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Vertex Pharmaceuticals specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Vertex Pharmaceuticals's P/E ratio high or low?

Accepted Answer

Vertex Pharmaceuticals's P/E ratio of 27.9× is above its own 5-year average of 25.9× and above the sector median of 24.2×. That places the current reading at the 55th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Vertex Pharmaceuticals's historical P/E ratio range?

Accepted Answer

In the available daily series, Vertex Pharmaceuticals (VRTX) P/E ratio has ranged from a low of 18.9× in 2021 to a high of 233.6× in 2011. The 5-year average is 25.9× and the 5-year median is 26.2×.

Question 7

What was Vertex Pharmaceuticals's P/E ratio in 2025?

Accepted Answer

Vertex Pharmaceuticals (VRTX) P/E ratio at the end of 2025 was 29.1×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Vertex Pharmaceuticals's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$115B	$3.95B	29.1×	—	Dec 31, 2025
2024	$104B	-$536M	—	—	Dec 31, 2024
2023	$105B	$3.62B	29.0×	+6.6×	Dec 31, 2023
2022	$74.2B	$3.32B	22.3×	-1.5×	Dec 31, 2022
2021	$55.9B	$2.34B	23.9×	+1.2×	Dec 31, 2021
2020	$61.5B	$2.71B	22.7×	-25.3×	Dec 31, 2020
2019	$56.5B	$1.18B	48.0×	+27.9×	Dec 31, 2019
2018	$42.2B	$2.1B	20.1×	-122.9×	Dec 31, 2018
2017	$37.7B	$263M	143.1×	—	Dec 31, 2017
2016	$18.1B	-$115M	—	—	Dec 31, 2016
2015	$30.1B	-$558M	—	—	Dec 31, 2015
2014	$28.3B	-$739M	—	—	Dec 31, 2014
2013	$17.2B	-$445M	—	—	Dec 31, 2013
2012	$8.99B	-$107M	—	—	Dec 31, 2012
2011	$6.91B	$29.6M	233.6×	—	Dec 31, 2011
2010	$7.05B	-$755M	—	—	Dec 31, 2010
2009	$8.52B	-$642M	—	—	Dec 31, 2009
2008	$4.52B	-$460M	—	—	Dec 31, 2008
2007	$3.04B	-$391M	—	—	Dec 31, 2007
2006	$4.64B	-$207M	—	—	Dec 31, 2006
2005	$2.97B	-$203M	—	—	Dec 31, 2005
2004	$836M	-$166M	—	—	Dec 31, 2004
2003	$805M	-$153M	—	—	Dec 31, 2003
2002	$1.21B	-$109M	—	—	Dec 31, 2002


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Vertex Pharmaceuticals (VRTX) 2011-2026

P/E Ratio daily chart for Vertex Pharmaceuticals (VRTX)

Historical P/E Ratio for Vertex Pharmaceuticals (VRTX) from 2002 to 2025

About P/E Ratio at Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals P/E Ratio by Year

Vertex Pharmaceuticals P/E Ratio 2025: 29.1×

Vertex Pharmaceuticals P/E Ratio 2023: 29.0×

Vertex Pharmaceuticals P/E Ratio 2022: 22.3×

Vertex Pharmaceuticals P/E Ratio 2021: 23.9×

Vertex Pharmaceuticals P/E Ratio 2020: 22.7×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Vertex Pharmaceuticals (VRTX) Key Financials